adefovir

(redirected from Adefovir dipivoxil)
Also found in: Medical.
Related to Adefovir dipivoxil: Entecavir, Tenofovir
Translations

adefovir

n adefovir m
References in periodicals archive ?
NNRTIs include tenofovir and adefovir dipivoxil (Hepsera[R]).
Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B.
There are six approved drug therapies including small molecule nucleoside analogues lamivudine, entecavir, and telbivudine, acyclic nucleotide analog adefovir dipivoxil, and injection proteins interferon alfa-2b and pegylated interferon alfa-2a for the treatment of chronic hepatitis B virus infection [1].
Contract notice: Drugs under the program the drug for hepatitis: adefovir dipivoxil for obserwacyjno-division of infectious diseases and liver diseases in healthcare complex in debica.
Other Sigmapharm releases include Liothyronine Sodium Tablets, for hypothyroidism, which is the most stable Liothyronine product on the market with a shelf life of 36 months; Adefovir Dipivoxil Tablets, for hepatitis B, which is the first and only generic product equivalent to Hepsera Tablets; and Sodium Phenylbutyrate Powder, for urea cycle disorders, which is the first and only generic product equivalent to Buphenyl Powder.
Nucleotide analog, the leading antiviral product for the treatment of CHB, has such main varieties as entecavir, adefovir dipivoxil, lamivudine, telbivudine, emtricitabine and tenofovir disoproxil in the clinic.
Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials.
8 Among the nucleoside analogues Lamivudine, Adefovir dipivoxil, Entecavir (ETV) and LdT have been approved by the United States FDA for the treatment of HBV.
However, the efficacy of this strategy and the need for combined therapy with adefovir dipivoxil in patients who select Lamivudine-resistant strains before surgery is still unknown.
More recently, the nucleotide analogue adefovir dipivoxil, the prodrug of adefovir, was licensed for treatment of chronic hepatitis B10.
Adefovir dipivoxil is active against HBV but not against HIV at the 10 mg dose; however, there is a theoretical risk of development of HIV resistance, as it has anti-HIV activity at higher doses and is related to tenofovir.
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.